News
Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression
January 10, 2024
Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024
December 21, 2023
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
November 3, 2023
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
June 5, 2023
ALK-001 (C20-D3-Vitamin A) slows the growth of atrophic lesions in ABCA4-related Stargardt Disease: Results of a Phase 2 placebo-controlled clinical trial (TEASE study)
June 1, 2022
C20D3-Vitamin A Prevents Retinal Pigment Epithelium Atrophic Changes in a Mouse Model
December 1, 2021
Alkeus Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 29, 2021
Vitamin A cycle byproducts impede dark adaptation
September 1, 2021